Compliance leaders moving between health plans and traditional insurance often carry assumptions that do not transfer. Drug testing is one of the clearest examples. In traditional insurance, drug screening programs are frequently minimal or absent altogether. In managed care, drug testing sits inside a much larger web of regulatory obligation, provider risk, and member safety. Treating the two as interchangeable creates gaps that show up later as audit findings, budget overruns, or hiring delays.
Why Insurance and Managed Care Diverge on Drug Testing
Traditional insurance carriers underwrite risk. Managed care organizations deliver care, coordinate networks of providers, and often employ or contract staff who interact directly with vulnerable populations, including Non-Emergency Medical Transportation (NEMT) drivers, utilization management nurses, and credentialed clinicians. That operational reality changes what regulators expect.
MCOs are subject to layered requirements that a traditional insurer rarely encounters:
- Continuous exclusion screening against the OIG List of Excluded Individuals/Entities (LEIE) and the System for Award Management (SAM), not just a one-time check at hire
- Section 1033 felony screening under federal law, which restricts individuals with dishonesty or breach-of-trust convictions from working in insurance or managed care roles without a written waiver
- Motor vehicle record monitoring for transport staff, refreshed quarterly or semi-annually rather than reviewed once
-
Occupational health and titer compliance tied to direct patient contact
Drug testing fits into this framework as one control among several, and its scope depends heavily on role, contract terms, and state requirements. A compliance program built for a general insurance workforce will not account for any of this.
Where This Plays Out: Screening Policy, Vendor Expectations, and Budget
Screening policy. Many managed care organizations discover mid-audit that their drug testing policy was inherited from a parent company or benchmarked against a general insurance peer, rather than built around the roles that actually carry regulatory exposure. NEMT drivers, clinicians with prescribing authority, and staff with facility access typically warrant different protocols than back-office administrative roles.
Vendor expectations. Vendors who serve general insurance clients are not always equipped to handle the volume, geographic spread, or documentation standards managed care requires. A screening partner needs to understand exclusion databases, licensing boards, and audit-ready reporting, not just deliver a drug panel result.
Budget allocation. When drug testing decisions are made without a clear framework, organizations tend to either over-test low-risk roles or under-test high-risk ones. Both are expensive. Over-testing adds unnecessary cost and slows hiring. Under-testing creates liability that surfaces during a CMS audit or after an incident involving a member.
A Simple Framework: When to Test, When It’s Optional, and When It’s Wasted Spend
When you must test. Roles governed by state Medicaid managed care contracts, federal transportation safety rules, or specific payer requirements. NEMT drivers and clinical staff with direct patient contact usually fall here, along with any role explicitly named in a network participation agreement.
When you should test. Roles with elevated but not explicitly mandated risk, such as care coordinators handling protected health information or administrative staff with facility access. These decisions benefit from a documented rationale so compliance teams can defend the policy during an audit.
When it’s wasted spend. Roles with no patient contact, no facility access, and no contractual requirement. Applying a blanket testing policy here adds cost and friction without reducing measurable risk and no federal funding
Mapping roles against this framework, rather than applying a single company-wide policy, is the fastest way to close compliance gaps and eliminate unnecessary spend at the same time.
Designing Compliance-Aligned, Cost-Aware Programs
Getting this right requires more than a policy update. It requires visibility into what is actually happening across labs, locations, and role categories, along with a screening partner who understands the regulatory environment specific to managed care rather than applying general insurance assumptions.
UBS works with managed care organizations to build screening programs mapped to actual regulatory exposure by role, combining exclusion monitoring, license verification, and drug testing into a single coordinated workflow instead of a patchwork of disconnected vendors. The result is a program compliance teams can defend in an audit and finance teams can explain in a budget review.
If your organization is still running one drug testing policy across every role type, it is worth asking which of the three categories above each role actually falls into. That single exercise often reveals both the compliance gap and the wasted spend in the same conversation.
Interested in mapping your workforce against managed care compliance requirements? Connect with UBS to discuss a screening program built for your risk profile vs a generic template.
